EMA: On­go­ing study da­ta of Cell­tri­on’s mAb enough to al­low its use in some Covid-19 pa­tients

The Eu­ro­pean Med­i­cines Agency added an­oth­er mon­o­clon­al an­ti­body to the con­ti­nent’s Covid-19 ther­a­peu­tics ar­se­nal on Fri­day, con­clud­ing that Cell­tri­on’s reg­dan­vimab can be used as a treat­ment for adults with Covid-19 who do not re­quire sup­ple­men­tal oxy­gen and who are at high risk of pro­gress­ing to se­vere Covid-19.

The EMA said its rec­om­men­da­tion is based on a re­view of da­ta from the first part of an on­go­ing study show­ing reg­dan­vimab may low­er the rate of hos­pi­tal­iza­tions in adult out­pa­tients with Covid-19 symp­toms de­scribed as mild to mod­er­ate who do not need sup­ple­men­tal oxy­gen.

“How­ev­er, the re­sults were not ro­bust enough to reach a firm con­clu­sion on the med­i­cine’s ben­e­fits at this point in time,” EMA said. “In terms of safe­ty, most side ef­fects re­port­ed were mild or mod­er­ate. Re­ac­tions re­lat­ed to the in­fu­sion (in­clud­ing al­ler­gic re­ac­tions) can­not be ex­clud­ed and health­care pro­fes­sion­als should mon­i­tor pa­tients for these re­ac­tions.”

De­spite the un­cer­tain­ties, EMA con­clud­ed that reg­dan­vimab can be con­sid­ered a treat­ment op­tion for pa­tients at high risk of pro­gress­ing to se­vere Covid-19, based on a rea­son­able like­li­hood that the med­i­cine may pro­vide clin­i­cal ben­e­fit, and a low like­li­hood of harm.

Cell­tri­on said in Feb­ru­ary that its mAb, al­so known as CT-P59, re­duced the rate of pro­gres­sion to se­vere Covid-19 by 54% for pa­tients with mild-to-mod­er­ate symp­toms and 68% for mod­er­ate pa­tients aged 50 years and over.

A glob­al Phase III clin­i­cal tri­al is still re­cruit­ing and is ex­pect­ed to en­roll 1,172 pa­tients with mild-to-mod­er­ate symp­toms of Covid-19 at more than 10 glob­al sites to eval­u­ate the ef­fi­ca­cy and safe­ty of the treat­ment.

While the an­ti­body treat­ment is cur­rent­ly not au­tho­rized in the EU, the EMA’s rec­om­men­da­tion on Fri­day pro­vides a har­mo­nized sci­en­tif­ic opin­ion at the EU lev­el to sup­port na­tion­al de­ci­sion mak­ing on the pos­si­ble use of it. A rolling re­view by the EMA for reg­dan­vimab, which start­ed in late Feb­ru­ary, is on­go­ing and will be the ba­sis for a mar­ket­ing ap­proval, the agency said. The US FDA has yet to au­tho­rize the Cell­tri­on mon­o­clon­al an­ti­body.

Cell­tri­on al­so said the Ko­rea Dis­ease Con­trol and Pre­ven­tion Agency has as­sessed and in­de­pen­dent­ly con­firmed that the mAb suc­cess­ful­ly neu­tral­izes the SARS-CoV-2 vari­ants first iden­ti­fied in the UK (B.1.1.7) in ad­di­tion to the pre­vi­ous­ly iden­ti­fied six vari­ant genome mu­ta­tions of the nov­el coro­n­avirus. They al­so said that a cock­tail ther­a­py of CT-P59 with an­oth­er mAb can­di­date demon­strat­ed neu­tral­iz­ing ca­pa­bil­i­ties against the vari­ants orig­i­nat­ing in the UK and South Africa (B.1.351).

Un­pack­ing the Aduhelm de­ci­sion, Ver­tex's half full glass, a $525M J&J breakup, and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

By now you have surely read about the FDA’s controversial approval of Biogen’s Alzheimer’s drug and all its reverberations. But I’d still recommend checking out the meaty recap below to make sure you didn’t miss all the angles that the Endpoints team has covered. If you’d rather look ahead, look no further than our three-day virtual panels next week at BIO, where we will discuss what the new normal means for every part of the industry.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.

Aaron Kesselheim (Scott Eisen/AP Images for AIDS Healthcare Foundation)

Har­vard’s Aaron Kessel­heim re­signs from ex­pert pan­el in wake of ad­u­canum­ab OK, blast­ing FDA for ‘worst drug ap­proval de­ci­sion in re­cent U.S. his­to­ry'

A third member of the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee has resigned in the wake of Biogen’s controversial Aduhelm approval, slamming the agency as he left and further deepening the controversy surrounding the decision.

Harvard University professor Aaron Kesselheim quit in protest Thursday afternoon, calling the Aduhelm OK “probably the worst drug approval decision in recent U.S. history.” Kesselheim follows both Joel Perlmutter, a neurologist from Washington University in St. Louis, and David Knopman, a neurologist from the Mayo Clinic, out the door.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.

David Knopman (Mayo Clinic via YouTube)

A sec­ond ad­comm mem­ber aban­dons his post in af­ter­math of con­tro­ver­sial ad­u­canum­ab de­ci­sion

As the fallout from the FDA’s approval of Alzheimer’s med aducanumab grows, a second member of the adcomm overseeing that drug’s review has walked away. But even with two experts now having resigned from that committee in protest, is there enough broad-level outrage to prevent another aducanumab from getting approved?

The FDA on Wednesday lost another member of its Peripheral and Central Nervous System Drugs Advisory Committee as Mayo Clinic neurologist David Knopman hit the exit over the agency’s decision to approve Biogen’s Alzheimer’s drug Aduhelm despite the committee’s near-unanimous vote against it.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.

What does a clear ma­jor­i­ty of the bio­phar­ma in­dus­try think of the FDA ap­proval of ad­u­canum­ab? 'Hor­ri­fy­ing' 'Dan­ger­ous' 'Con­fus­ing' 'Dis­as­ter'

Over the years, we’ve become used to seeing a consensus emerge early in our industry polls at Endpoints News. And when we took the pulse of drug hunters on the heels of a controversial FDA approval for aducanumab this week, it became immediately apparent that the vast majority of our readers — heavily concentrated among biopharma staffers and execs — were incensed by what they had just witnessed.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 109,100+ biopharma pros reading Endpoints daily — and it's free.

FDA au­tho­rizes about 10M J&J vac­cine dos­es, trash­es 60M more from trou­bled Emer­gent plant

The FDA on Friday released about 10 million doses of J&J’s vaccine for use, and disposed of another 60 million doses that were manufactured at the now-shuttered Emergent BioSolutions facility in Baltimore where cross-contamination occurred.

The agency said it’s not yet ready to allow the Emergent plant to be included in the J&J EUA, but that may occur soon. FDA came to the decision to authorize some of the doses after reviewing facility records and quality testing results.

FDA plans new stud­ies on ac­cel­er­at­ed ap­proval dis­clo­sures in bio­phar­ma ads

When people read biopharma companies’ websites about new drugs approved via the FDA’s accelerated pathway, like Biogen’s new Alzheimer’s drug, do they understand that these drugs may only be reasonably likely to predict clinical benefit and still require confirmatory studies?

That’s what the FDA’s Office of Prescription Drug Promotion wants to firm up as an agency analysis of direct-to-consumer websites for accelerated approval drugs previously found that only 21% of the disclosures used language directly from the label.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

As it ex­pands its foot­print, Mod­er­na reach­es deal to man­u­fac­ture Covid-19 vac­cine dos­es in Mid­dle East

While the UAE leads the world with the highest percentage of residents vaccinated, neighboring Saudi Arabia — home to nearly 35 million people — has lagged behind significantly. On Friday, Moderna announced that it has partnered with the Saudi pharmaceutical company Tabuk to manufacture its jab and future variant-specific boosters in the country.

Tabuk will hold marketing authorization for the vaccine in Saudi Arabia, and the agreement gives them the possibility of distributing future Moderna mRNA products.

An ex­pen­sive watch, shell com­pa­nies and fake in­voic­es: How two Is­raeli traders tapped in­to a $100M glob­al biotech in­sid­er trad­ing ring

It appears that we have reached the end of the saga about the global insider trading ring that collectively reaped $100 million from placing “timely, profitable” trades in biotech stocks like Ariad, Pharmacyclics and Receptos.

Tomer Feingold and Dov Malnik — Israeli traders living in Switzerland — were the last out of eight to be charged as the SEC unraveled the scheme, which ran from 2013 through 2017. Together, according to a statement in March, the pair had pocketed more than $4 million.

Covid-19 roundup: 60 mil­lion J&J dos­es from Emer­gent to be tossed; EMA up­dates As­traZeneca vac­cine warn­ings

After a two-month hold on millions of doses of the J&J vaccine, the FDA will announce that it is releasing 10 million doses and trashing 60 million that were made at a troubled Baltimore plant, The New York Times scooped on Friday morning.

Emergent BioSolutions reported that the doses were contaminated after drug material intended for the AstraZeneca vaccine came in close contact with media prepared for a J&J run. As a result, the doses were held from distribution, causing a shakeup in early availability.